脱皮化疗可以克服复发性耐火性多发性髓瘤中对teclistamab的初级耐药性

Rintu Sharma1, Andree-Anne Pelland2, Katherine Lajkosz3

  • 1Princess Margaret Cancer Centre Toronto, ON Canada.

Blood cancer discovery
|March 11, 2026
PubMed
概括

识别多发性骨髓瘤 (MM) 的高风险因素至关重要. 脱化疗可以改善对特克利斯塔马布等双特异性抗体的反应,在具有初级耐药性的患者中.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K